Scandion Oncology (SCOL)

Executive Summary

Scandion Oncology was a clinical-stage biotechnology company based in Copenhagen, Denmark, focused on overcoming cancer drug resistance. Its core technology involved inhibiting drug efflux pumps and modulating specific targets to reverse resistance to existing chemotherapies. The company was listed on the Nasdaq First North Growth Market Sweden under the ticker SCOL. Unfortunately, Scandion Oncology ceased operations and entered liquidation in 2025, marking the end of its efforts to develop therapies for drug-resistant cancers. Despite its innovative approach to addressing a critical unmet need in oncology, the company was unable to sustain operations or secure sufficient capital to continue development.